Oncologists, aware that patients are paying the costs of expensive cancer drugs, are declining to prescribe medicines that have scant or no effect.» Read More
Irene Tse, who headed the North America operations of the Chief Investment Office, told the firm she is resigning to focus on "entrepreneurial ventures," according to a memo on Monday from Chief Operating Officer Matt Zames, a copy of which was obtained by Reuters.
He will be based in London. Willett joins from Royal Bank of Scotland, where most recently he was chairman of corporate finance for Europe, the Middle East and Africa. A top Morgan Stanley broker, Jonathan Madrigano, who last year managed about $2 billion in client assets left the company's brokerage division on Friday to join J.P. Morgan Securities.
The bank named Tom Willett as head of mergers and acquisitions, Europe. He will be based in London. Willett joins from Royal Bank of Scotland, where most recently he was chairman of corporate finance for Europe, the Middle East and Africa.
FRANKFURT, Oct 1- Evotec AG:. *Evotec and Bayer enter into multi-target alliance to fight endometriosis. up to approximately euro 580 million.
When we began planning our special report "Women in Business," I was eager to learn about how women are really doing in the workplace. In short, many women are successful, powerful and well off, but progress in the professional world has stalled.
With both global food prices and concerns about food safety on the rise, technology is playing a more important role in the economics of the world’s food supply.
An airplane needs to be safe in order for passengers to board it. Likewise, an airline CEO wants to feel the same clarity and certainty that so many of his c-suite compadres do in order to sustain growth.
European shares are indicated to open flat Friday, ahead of a conference at the European Central Bank in Frankfurt where Fed Chairman Ben Bernanke and ECB President Jean-Claude Trichet will both speak.
The jobs crisis has brought an unwelcome discovery for many unemployed Americans: job openings in their old fields exist. Yet they no longer qualify for them.
Shares in European airline and travel stocks fell heavily on Monday as ash from an Icelandic volcano looked set to bring much of Europe to a standstill for a 5th straight day.
I didn’t inhale. It’s the truth. I swear. I have never ever taken a toke on a joint or even a cigarette. Growing up, my parents were both smokers and I think I developed such a distaste for the constant cloud that it just never held any appeal for me.
At the risk of getting more emails from conspiracy-theorist readers who think I report too much negative news about Pfizer, here comes another setback for the world's biggest drug company.
On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."
More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.
A study claims "the time has come" for researchers to study ED drugs as preventive medicine for the heart.
If you watch "Project Runway," the future of judge Nina Garcia has been up in the air since she left Elle. Now we know the sort of career opportunities she's exploring. Not developing a new clothing line, or another magazine job, or designing shoes.
I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.
Stocks ticked higher Monday amid merger buzz but index gains were modest as the market awaits the Federal Reserve's rate decision later this week.
Stocks retreated after an early pop Monday as the early market buzz was all about deals and deal makers.
Last night while on the elliptical and watching "NBC Nightly News," one spot amid the wall-to-wall commercials for drugs caught my attention. It looks like after 10 years since the first erectile dysfunction pill came on the market--Pfizer's Viagra celebrated a decade since winning FDA approval last week--the makers of Levitra are trying a new marketing tack.